| Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum A Huttner, S Harbarth, J Carlet, S Cosgrove, H Goossens, A Holmes, ... Antimicrobial resistance and infection control 2, 1-13, 2013 | 605 | 2013 |
| Phase 1 trials of rVSV Ebola vaccine in Africa and Europe ST Agnandji, A Huttner, ME Zinser, P Njuguna, C Dahlke, JF Fernandes, ... New England Journal of Medicine 374 (17), 1647-1660, 2016 | 516 | 2016 |
| Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials A Huttner, EM Verhaegh, S Harbarth, AE Muller, U Theuretzbacher, ... Journal of Antimicrobial Chemotherapy 70 (9), 2456-2464, 2015 | 333 | 2015 |
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial A Huttner, JA Dayer, S Yerly, C Combescure, F Auderset, J Desmeules, ... The Lancet Infectious Diseases 15 (10), 1156-1166, 2015 | 328 | 2015 |
| An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units G Wong, A Brinkman, RJ Benefield, M Carlier, JJ De Waele, N El Helali, ... Journal of antimicrobial chemotherapy 69 (5), 1416-1423, 2014 | 252 | 2014 |
| Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage A Huttner, J Bielicki, MN Clements, N Frimodt-Møller, AE Muller, ... Clinical Microbiology and Infection 26 (7), 871-879, 2020 | 249 | 2020 |
| Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial A Huttner, A Kowalczyk, A Turjeman, T Babich, C Brossier, N Eliakim-Raz, ... Jama 319 (17), 1781-1789, 2018 | 244 | 2018 |
| Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study A Huttner, E Von Dach, A Renzoni, BD Huttner, M Affaticati, L Pagani, ... International journal of antimicrobial agents 45 (4), 385-392, 2015 | 241 | 2015 |
| Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract … A Huttner, C Hatz, G van den Dobbelsteen, D Abbanat, A Hornacek, ... The Lancet infectious diseases 17 (5), 528-537, 2017 | 214 | 2017 |
| Effect of C-reactive protein–guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram … E von Dach, WC Albrich, AS Brunel, V Prendki, C Cuvelier, D Flury, ... Jama 323 (21), 2160-2169, 2020 | 210 | 2020 |
| Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? A Huttner, S Harbarth, WW Hope, J Lipman, JA Roberts Journal of Antimicrobial Chemotherapy 70 (12), 3178-3183, 2015 | 202 | 2015 |
| Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study AG L'Huillier, B Meyer, DO Andrey, I Arm-Vernez, S Baggio, ... Clinical Microbiology and Infection 27 (5), 784. e1-784. e8, 2021 | 144 | 2021 |
| Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? AE Muller, B Huttner, A Huttner Drugs 78 (4), 439-451, 2018 | 137 | 2018 |
| Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study T Huwyler, L Lenggenhager, M Abbas, KI Lorenzini, S Hughes, B Huttner, ... Clinical Microbiology and Infection 23 (7), 454-459, 2017 | 136 | 2017 |
| How to use biomarkers of infection or sepsis at the bedside: guide to clinicians P Póvoa, L Coelho, F Dal-Pizzol, R Ferrer, A Huttner, A Conway Morris, ... Intensive care medicine 49 (2), 142-153, 2023 | 134 | 2023 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in the upper respiratory tract of children and adults with early acute coronavirus disease 2019 (COVID-19) S Baggio, AG L’Huillier, S Yerly, M Bellon, N Wagner, M Rohr, A Huttner, ... Clinical Infectious Diseases 73 (1), 148-150, 2021 | 134 | 2021 |
| Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV A Rechtien, L Richert, H Lorenzo, G Martrus, B Hejblum, C Dahlke, ... Cell reports 20 (9), 2251-2261, 2017 | 131 | 2017 |
| Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline RA Wijma, A Huttner, BCP Koch, JW Mouton, AE Muller Journal of Antimicrobial Chemotherapy 73 (11), 2916-2926, 2018 | 128 | 2018 |
| New and improved? A review of novel antibiotics for Gram-positive bacteria M Abbas, M Paul, A Huttner Clinical Microbiology and Infection 23 (10), 697-703, 2017 | 101 | 2017 |
| Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials AE Muller, EM Verhaegh, S Harbarth, JW Mouton, A Huttner Clinical Microbiology and infection 23 (6), 355-362, 2017 | 96 | 2017 |
